Nav: Home

When cancer of unknown origin strikes, patient's family members face increased risk

December 17, 2015

(SALT LAKE CITY)--Cancer usually begins in one location and then spreads, but in 3 percent to 5 percent of cancer patients, the tissue where a cancer begins is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called "cancers of unknown primary," or CUP, have a very poor prognosis, with a median survival of three months. A new study in the JAMA Oncology finds that family members of CUP patients are at higher risk of developing CUP themselves, as well as cancers of the lung, pancreas, colon and some cancers of the blood.

Jewel Samadder, M.D., is the lead researcher on the University of Utah and Huntsman Cancer Institute (HCI) study. He said he was motivated to do the study when he had a patient that presented with abnormal fluid accumulation in his abdomen. They removed the fluid and found cancer cells, but could never find the primary source of the cancer, even after an extensive search involving imaging and endoscopy.

"The relatives were very distraught and we had very little that we could tell them about where the cancer started from in their loved one and whether they, as family members, were at increased risk for cancer," he said.

Also upsetting to CUP patients and family members, according to Samadder, is the difficulty physicians have in determining the best course of therapy to recommend. "Because we are not able to identify the primary tumor site, we are not able to select a type of chemotherapy or radiotherapy that the cancer would respond to best."

He adds that the inability to select the best therapy and the advanced nature of these cancers are likely responsible for the poor outcomes.

To understand the familial risk associated with CUP and to determine where these cancers may have originated in the body, the researchers decided to do a retrospective study where they looked at CUP patients and their families between 1980 and 2010.

The study was possible because of a unique resource at HCI called the Utah Population Database (UPDB), which links genealogy information of Utah families with demographic and medical information, including the Utah Cancer Registry, a statewide cancer archive that collects all incidents of cancer diagnoses in the state.

Using these databases, researchers were able to identify 4,160 patients diagnosed with CUP over a 30-year span and to identify which of these patients had family members that were also diagnosed with cancer. These data were used to calculate the cancer risk by site for first-degree (parents, siblings, children), second-degree (uncles, aunts, grandparents, nephews, nieces), and first cousin relatives compared to randomly selected matched population controls who were cancer free.

According to Samadder, "The study could have gone two ways. One way is that relatives are not at increased risk of any one cancer, that cancer of unknown primary is some sort of bad luck event. But we didn't find that. We found that there are certain cancers that seem to be of increased risk in close, and even distant family members. In first-degree relatives, the most important ones we identified are lung, pancreatic, and colon cancer."

The researchers found that first-degree relatives of a CUP patient have a 35 percent increased risk for CUP, 37 percent increased risk for lung cancer, 28 percent increased risk for pancreatic cancer, and 20 percent increased risk for colorectal cancer when compared to relevant control populations.

Samadder said he can now give some important information to relatives of CUP patients about their cancer risk and ways in which they may try to moderate this risk. "What is important about lung, pancreas, and colon cancer is that two of these, lung and pancreas, are smoking-related cancers. So we can advocate to family members to avoid smoking. For colon cancer we can recommend screening guidelines, such as regular colonoscopies, to try to mitigate against the risk."

Samadder added, "This paper also suggests that these tissues, such as lung, pancreas, and colon may be the primary sites for at least a portion of these cancers of unknown primary."

He said in the future this study may give guidance to physicians on which tissues to look at more closely when they have a CUP patient and possible therapies that might work better in these patients. "It opens up a new avenue of research, a new way of looking at the biology of cancers of unknown primary to see if it looks like they are really coming from one of these sites, and if so, should chemotherapy be tailored to one of these sites because that may be better than giving a chemotherapy that has no tailoring at all."
Samadder and co-authors, Ken Robert Smith, Heidi Hanson, Richard Pimentel, Jathine Wong, Kenneth Boucher, Wallace Akerley, Glynn Gilcrease, Cornelia M. Ulrich, Randall W. Burt, and Karen Curtin are from Huntsman Cancer Institute and the University of Utah.

This work was supported by the National Cancer Institute P30 CA042014, Huntsman Cancer Foundation, and the American College of Gastroenterology.

About Huntsman Cancer Institute at the University of Utah

Huntsman Cancer Institute (HCI) is one of the world's top academic research and cancer treatment centers. HCI manages the Utah Population Database - the largest genetic database in the world, with more than 16 million records linked to genealogies, health records, and vital statistics. Using this data, HCI researchers have identified cancer-causing genes, including the genes responsible for melanoma, colon and breast cancer, and paraganglioma. HCI is a member of the National Comprehensive Cancer Network (a 26-member alliance of the world's leading cancer centers) and is a National Cancer Institute-Designated Comprehensive Cancer Center. HCI treats patients with all forms of cancer and operates several high-risk clinics that focus on melanoma and breast, colon, and pancreas cancers. The HCI Cancer Learning Center for patient and public education contains one of the nation's largest collections of cancer-related publications. The institute is named after Jon M. Huntsman, Sr., a Utah philanthropist, industrialist, and cancer survivor.

University of Utah Health Sciences

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...